Subtotal $0.00
Shop Now
This GLP-1 drugs list covers every GLP-1-based medicine on the U.S. market as of October 2026. Six active ingredients are currently approved: exenatide (now sold only as a generic), liraglutide (Victoza, Saxenda and generics), dulaglutide (Trulicity), semaglutide (Ozempic, Rybelsus, Ozempic tablets, Wegovy), tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo). Some are approved for type 2 diabetes, some for weight management, and several carry extra uses such as lowering cardiovascular risk. Byetta, Bydureon, Tanzeum and Adlyxin have been discontinued. All require a prescription, and compounded or “research” versions are not FDA-approved drugs.
Peptide Labs does not sell Ozempic, Wegovy, Mounjaro, Zepbound or any prescription drug. This article summarizes FDA records and prescribing information. For how this class of medicines works, see our explainer on what GLP-1 is.
Key Takeaways
- Six GLP-1-based active ingredients are FDA-approved and on the U.S. market in 2026.
- Tirzepatide acts on GIP and GLP-1 receptors; orforglipron is a small-molecule pill.
- Weight management approvals: Saxenda and its generics, Wegovy, Zepbound and Foundayo.
- Generic exenatide and generic liraglutide exist; no generic semaglutide or tirzepatide is on sale.
- Byetta, Bydureon, Tanzeum and Adlyxin are no longer sold in the U.S.
- Compounded and research-labeled GLP-1 products are not on any FDA-approved list.
GLP-1 drugs list: FDA-approved brands on the market in 2026
The table is a list of GLP-1 medications currently marketed in the U.S., with the date of first FDA approval from the agency’s Drugs@FDA database. T2D means type 2 diabetes. Approved uses are condensed from each product’s prescribing information.
| Brand | Active ingredient | Form | Main approved uses | First FDA approval |
|---|---|---|---|---|
| Victoza and generics | Liraglutide | Daily injection | Blood sugar control in T2D, ages 10 and up | January 2010 |
| Saxenda and generics | Liraglutide | Daily injection | Weight management, adults and ages 12 and up | December 2014 |
| Trulicity | Dulaglutide | Weekly injection | Blood sugar control in T2D, ages 10 and up; heart risk reduction in T2D | September 2014 |
| Ozempic | Semaglutide | Weekly injection | Blood sugar control in T2D; heart and kidney risk reduction in T2D | December 2017 |
| Rybelsus and Ozempic tablets | Semaglutide | Daily tablet | Blood sugar control in T2D; heart risk reduction in T2D | September 2019 (Ozempic tablet name 2026) |
| Wegovy injection | Semaglutide | Weekly injection | Weight management, adults and ages 12 and up; heart risk reduction; MASH liver disease | June 2021 |
| Wegovy tablets | Semaglutide | Daily tablet | Weight management in adults; heart risk reduction | December 2025 |
| Mounjaro | Tirzepatide (GIP and GLP-1) | Weekly injection | Blood sugar control in T2D, ages 10 and up; heart risk reduction in T2D | May 2022 |
| Zepbound | Tirzepatide (GIP and GLP-1) | Weekly injection | Weight management in adults; moderate to severe obstructive sleep apnea with obesity | November 2023 |
| Foundayo | Orforglipron (small molecule) | Daily tablet | Weight management in adults | April 2026 |
| Generic exenatide | Exenatide | Twice-daily injection | Blood sugar control in T2D | November 2024 (generic) |
Two once-daily insulin combination injections also contain a GLP-1 ingredient: Soliqua (insulin glargine with lixisenatide) and Xultophy (insulin degludec with liraglutide), both approved in November 2016 for type 2 diabetes. They are usually counted as insulin products rather than standalone GLP-1 drugs.
GLP-1 receptor agonists list by approved use
A GLP-1 receptor agonists list is easier to use when it is sorted by what each medicine is approved to do. The same molecule can sit under different brand names for different uses, which is why semaglutide appears as Ozempic for diabetes and Wegovy for weight management. Our Wegovy and Ozempic comparison and Mounjaro and Zepbound comparison explain those pairs.
- Type 2 diabetes: Victoza and generic liraglutide, Trulicity, Ozempic injection, Rybelsus and Ozempic tablets, Mounjaro and generic exenatide.
- Chronic weight management: Saxenda and generic liraglutide, Wegovy injection and tablets, Zepbound and Foundayo.
- Lowering the risk of heart attack, stroke or cardiovascular death: Trulicity, Ozempic, Rybelsus and Ozempic tablets and Mounjaro in type 2 diabetes; Wegovy in people with established heart disease and obesity or overweight.
- Other approved uses: Ozempic for kidney risk in type 2 diabetes with chronic kidney disease, Zepbound for obstructive sleep apnea with obesity, and Wegovy injection for MASH, a fatty liver disease, with moderate to advanced scarring.
- Children and teens: Victoza, Trulicity and Mounjaro are labeled for type 2 diabetes from age 10; Saxenda and Wegovy injection for weight management from age 12.
Using a diabetes brand purely for weight loss is off-label, a decision only a prescriber can make. Every product on the list shares the same class warnings, including a boxed warning about thyroid C-cell tumors seen in rodents; see GLP-1 side effects across the class.
FDA-approved GLP-1 drugs: shots and tablets
Most FDA-approved GLP-1 drugs are peptides, which the stomach breaks down, so they are given by injection daily or weekly. Rybelsus, Ozempic tablets and Wegovy tablets get around this with an absorption enhancer and strict instructions about how they are taken; our guides to the Wegovy pill and oral semaglutide for diabetes cover them. Foundayo works differently: orforglipron is a small molecule rather than a peptide, so it is absorbed like an ordinary tablet. Our Foundayo guide explains what the label says.
Tirzepatide is also different. It activates the GIP receptor as well as the GLP-1 receptor, so it is often called a dual agonist. Our semaglutide vs tirzepatide article compares the two most prescribed molecules, and liraglutide vs semaglutide compares the daily and weekly options.
Generic GLP-1 drugs approved so far
Generics have reached the oldest members of the class. FDA records show:
- Exenatide: the first generic GLP-1 drug, referencing Byetta, approved in November 2024.
- Liraglutide for diabetes: the first generic referencing Victoza approved in December 2024, followed by several more from other manufacturers through 2026.
- Liraglutide for weight management: the first generic referencing Saxenda approved in August 2025.
- Semaglutide: one tentative approval in April 2026, which does not allow sale because of patents and exclusivity. Our guide to generic Ozempic explains the timeline.
- Dulaglutide and tirzepatide: no generic applications approved.
Discontinued GLP-1 drugs
Some names still appear in older articles and insurance lists but are no longer sold in the U.S. None was withdrawn for a safety problem; the companies cited business reasons.
- Byetta (exenatide, twice daily, approved 2005): brand discontinued in October 2024; generic exenatide remains.
- Bydureon and Bydureon BCise (exenatide extended-release, weekly, approved 2012 and 2017): discontinued, with BCise ending in October 2024.
- Tanzeum (albiglutide, weekly, approved 2014): discontinuation announced by GSK in 2017.
- Adlyxin (lixisenatide, daily, approved 2016): Sanofi stopped U.S. sales on January 1, 2023. Lixisenatide remains available inside Soliqua.
What does not belong on the list
Search results for GLP-1 drugs often mix in products that are not FDA-approved medicines:
- Investigational drugs such as retatrutide and CagriSema are still in trials or under FDA review. Our article on retatrutide side effects covers what trials have reported so far.
- Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA warns that salt forms such as semaglutide sodium are different active ingredients; see our compounding explainer.
- Products labeled “for research purposes” or “not for human consumption” are illegal to sell for people, according to the FDA. Our article on peptide legality explains the rules.
- “GLP-1” supplements and patches contain no GLP-1 drug. Our guide to GLP-1 support supplements explains what they are.
Frequently Asked Questions
What drugs are GLP-1 agonists?
FDA-approved GLP-1-based drugs in 2026 are exenatide, liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Rybelsus, Wegovy), tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo).
Which GLP-1 drugs are approved for weight loss?
Saxenda and its generics, Wegovy injection and tablets, Zepbound and Foundayo are approved for chronic weight management. Ozempic, Mounjaro and Trulicity are approved for type 2 diabetes.
Are there GLP-1 pills?
Yes. Rybelsus and Ozempic tablets for type 2 diabetes, and Wegovy tablets and Foundayo for weight management, are taken by mouth once a day.
Is there a generic GLP-1 drug?
Yes. Generic exenatide and generic liraglutide, for both diabetes and weight management, are FDA-approved. No generic semaglutide or tirzepatide can be sold in the U.S. yet.
Which GLP-1 drugs have been discontinued?
Byetta, Bydureon, Bydureon BCise, Tanzeum and Adlyxin are no longer sold in the U.S. The companies cited business reasons, not safety findings.
Is tirzepatide a GLP-1 drug?
Tirzepatide activates both the GLP-1 and GIP receptors, so it is a dual agonist. It is usually listed with GLP-1 drugs because it shares their main effects and warnings.
Peptide Labs does not sell GLP-1 medicines or any prescription drug. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.
Last reviewed October 2026.
Related guides: What Is GLP-1? The Hormone, How GLP-1 Drugs Work and Every FDA-Approved Option, Semaglutide vs Tirzepatide: How the Two Drugs Compare, Liraglutide vs Semaglutide: Daily vs Weekly GLP-1 Drugs Compared.